The US FDA has accepted and granted priority review to a supplemental Biologics License Application (sBLA) from Genentech for satralizumab (Enspryng; Genentech) for the treatment of thyroid eye disease (TED), with a PDUFA target date of October 15, 2026. If approved, satralizumab would represent the first subcutaneous, at-home treatment option for TED and the first IL-6 receptor inhibitor approved in the indication.
"The FDA's decision to grant priority review to Enspryng is an important step toward expanding treatment options for people living with thyroid eye disease," said Levi Garraway, MD, PhD, chief medical officer and head of Global Product Development at Genentech, in a statement.¹ "By targeting the underlying disease biology with a novel mechanism of action, this subcutaneous therapy has the potential to introduce a new treatment approach that combines clinical efficacy and a favorable safety profile with the convenience of at-home administration."¹
SatraGO phase 3 program: design and efficacy findings
The sBLA submission is based on results from SatraGO-1 (NCT05987423) and SatraGO-2 (NCT06106828), two identically designed, randomized, placebo-controlled, multicenter phase 3 trials conducted across 19 countries. The studies together enrolled 258 adults with either active, moderate-to-severe TED or chronic inactive TED. Participants were randomized 1:1 to receive satralizumab or placebo. Data from both trials were presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery annual meeting in October 2025.¹
The primary endpoint in both studies was the proportion of patients with active, moderate-to-severe TED who achieved at least a 2-mm reduction in proptosis in the study eye from baseline at week 24. In SatraGO-2, 53% of satralizumab-treated patients achieved this threshold compared with 23% in the placebo arm, a difference that met statistical significance. In SatraGO-1, 49% of satralizumab-treated patients versus 31% of placebo-treated patients achieved the primary endpoint; however, this difference did not reach statistical significance, and Genentech characterized SatraGO-1 as providing additional confirmatory evidence rather than a co-primary result.¹
Secondary outcomes across both studies included reductions in the clinical activity score (CAS), achieved in 78% to 90% of patients with active TED, and improvements in diplopia in 44% to 61% of patients with active TED in SatraGO-1 and SatraGO-2, respectively, according to the company.¹ No new safety signals were identified; the adverse event profile was consistent with satralizumab's established profile in neuromyelitis optica spectrum disorder, including risks of serious infection, elevated liver enzymes, and low neutrophil counts.¹ Peer-reviewed publication of the SatraGO data has not been confirmed at the time of this report, limiting independent assessment.
KEY FACTS
• Drug: Satralizumab (Enspryng; Genentech); IL-6 receptor inhibitor
• Proposed indication: moderate-to-severe TED (adults)
• Trial program: SatraGO-1 (NCT05987423) and SatraGO-2 (NCT06106828); phase 3
• Primary endpoint: ≥2-mm proptosis reduction at week 24
• SatraGO-2 result: 53% vs 23% placebo (statistically significant)
• SatraGO-1 result: 49% vs 31% placebo (not statistically significant)
• Secondary outcomes: CAS improvement in 78%–90%; diplopia improvement in 44%–61%
• Safety: No new signals; consistent with NMOSD profile
• Regulatory status: FDA priority review; PDUFA date October 15, 2026
• Current approval: NMOSD (US, EU, ~90 countries)
• Route of administration: Subcutaneous self-injection
Clinical context: unmet need in TED
TED, also known as Graves' ophthalmopathy, is a progressive, inflammatory autoimmune disease affecting periorbital and intraocular structures. It affects approximately 155 per 100,000 individuals and occurs most commonly in patients with hyperthyroidism, approximately half of whom experience at least mild disease manifestations.¹ Clinical features include proptosis, diplopia, eyelid retraction, orbital pain, and in severe cases, compressive optic neuropathy with risk of permanent vision loss.²
Currently approved therapies for TED include teprotumumab (TEPEZZA; Amgen), an insulin-like growth factor 1 receptor (IGF-1R) inhibitor administered as an intravenous infusion, which received FDA approval in 2020.³ While teprotumumab demonstrated significant proptosis reduction in randomized trials, its intravenous administration schedule limits access for some patients and imposes a clinical and logistical burden. In June 2026, the FDA approved a second IGF-1R inhibitor, veligrotug-vvze (Lumvoa; Viridian Therapeutics), also administered intravenously over a 12-week, five-infusion course; its approval covers both active and chronic TED, a broader label than teprotumumab's.⁵ A subcutaneous, self-administered option, if approved, would represent a meaningful shift in treatment convenience.
Drug background: satralizumab and IL-6 inhibition
Satralizumab is a humanized monoclonal antibody that targets the IL-6 receptor using recycling antibody technology, designed to allow for repeated receptor binding and sustained suppression of IL-6–mediated inflammatory signaling. IL-6 is implicated in orbital fibroblast activation and the inflammatory cascade underlying TED pathophysiology.⁴ The recycling mechanism theoretically prolongs drug half-life and enables sustained receptor blockade compared with conventional monoclonal antibody technologies.
Satralizumab is currently approved in approximately 90 countries, including the United States and European Union, for the treatment of AQP4 antibody-positive NMOSD in adults—a regulatory milestone from which its safety database of more than 10,000 patients is derived.¹ Genentech is also pursuing satralizumab in myelin oligodendrocyte glycoprotein antibody-associated disease and autoimmune encephalitis, with positive phase 3 MOGAD results recently announced and regulatory submissions planned.¹
Limitations and next steps
The priority review designation reflects the FDA's assessment that satralizumab may offer a meaningful advance over available therapies, though it does not predetermine approval. The failure of SatraGO-1 to meet its primary endpoint on statistical grounds warrants attention; regulators will likely scrutinize the totality-of-evidence interpretation the sponsor has advanced. Published peer-reviewed data and independent biostatistical evaluation will be important for a complete clinical assessment. The administration route—subcutaneous self-injection—provides a practical differentiation from teprotumumab, but comparative efficacy data between these agents are not available.
Key limitations of the current evidence base include the absence of peer-reviewed publication for SatraGO-1 and -2 at the time of this report, the mixed primary endpoint results across the two trials, and the lack of head-to-head comparative data with existing approved TED therapies. Long-term durability outcomes beyond week 24 and data in the chronic inactive TED population have not been detailed in available disclosures. The FDA decision is anticipated by October 15, 2026.
